Delcath Systems, Inc.

Equities

DCTH

US24661P8077

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 01:30:00 29/05/2024 am IST			5-day change	1st Jan Change
7.35 ^USD	-5.53%		-9.15%	+76.68%

28/05	Delcath Systems, Inc. Appoints Bridget Martell to Board of Directors	CI
15/05	HC Wainwright Adjusts Price Target on Delcath Systems to $22 From $20, Maintains Buy Rating	MT

Delcath Systems, Inc. Announces the Resignation of Jennifer K. Simpson from its Board of Directors, Effective June 1, 2020

May 23, 2020 at 01:37 am IST

Delcath Systems, Inc. announced that on May 18, 2020 Jennifer K. Simpson submitted her resignation from the Board of Directors of the Company. Simpson's resignation from the company's board of directors, effective on June 1, 2020. was not because of any disagreement with the company on any matter relating to the Company's operations, policies or practices.

Latest news about Delcath Systems, Inc.

Delcath Systems, Inc. Appoints Bridget Martell to Board of Directors	28/05	CI
HC Wainwright Adjusts Price Target on Delcath Systems to $22 From $20, Maintains Buy Rating	15/05	MT
Transcript : Delcath Systems, Inc., Q1 2024 Earnings Call, May 14, 2024	14/05
Stephens Starts Delcath Systems Wit Overweight Rating, $25 Price Target	14/05	MT
Earnings Flash (DCTH) DELCATH SYSTEMS Reports Q1 Revenue $3.1M, vs. Street Est of $2.2M	14/05	MT
Delcath Systems, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05	CI
Delcath Systems Says Phase 3 Data on Hepzato Kit Published in Oncology Journal	06/05	MT
Delcath Systems, Inc Announces Publication of Results from Pivotal FOCUS Study in Metastatic Uveal Melanoma Patients treated with HEPZATO KIT	06/05	CI
Delcath Systems Amends Supply, Manufacturing Agreement With Synerx Pharma, Mylan Teoranta for Melphalan Hydrochloride	26/04	MT
HC Wainwright Adjusts Delcath Systems' Price Target to $20 From $18, Maintains Buy Rating	27/03	MT
Earnings Flash (DCTH) DELCATH SYSTEMS Reports Q4 Revenue $539,000, vs. Street Est of $550,000	26/03	MT
Transcript : Delcath Systems, Inc., Q4 2023 Earnings Call, Mar 26, 2024	26/03
Delcath Systems, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/03	CI
Delcath Systems, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	26/03	CI
North American Morning Briefing : Markets Steady -2-	26/03	DJ
Delcath Systems, Inc. announced that it has received $7.00111 million in funding	20/03	CI
Delcath Systems Names Chief Operating Officer	19/03	MT
Delcath Systems, Inc. Appoints Martha S. Rook as Chief Operating Officer	19/03	CI
Delcath Systems, Inc. announced that it expects to receive $7.00111 million in funding	15/03	CI
Delcath Systems, Inc. Announces Healthcare Setting Locator for HEPZATO? KIT (melphalan/Hepatic Delivery System)	23/02	CI
Delcath Systems, Inc. Announces Executive Changes	15/02	CI
Delcath Systems Receives Permanent J-Code for HEPZATO? (melphalan/Hepatic Delivery System) Effective April 1, 2024	31/01	CI
Delcath Systems Launches Hepzato Kit in US for Treatment of Metastatic Uveal Melanoma	17/01	MT
Delcath Systems Announces U.S. Launch and First Commercial Treatment Utilizing Hepzato Kit?	16/01	CI
Delcath Systems Insider Bought Shares Worth $148,800, According to a Recent SEC Filing	21/11	MT

Chart Delcath Systems, Inc.

Duration

Period

More charts

Company Profile

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's products, HEPZATO KIT (Hepzato (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan (CHEMOSAT) percutaneous hepatic perfusion (PHP) are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATO KIT is a drug/device combination product designed to administer high-dose chemotherapy directly into the liver while limiting systemic exposure and associated side effects. In Europe, the hepatic delivery system is a stand-alone medical device having the same device components as HEPZATO KIT, but without the melphalan hydrochloride and is approved for sale under the trade name CHEMOSAT. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA).

Sector

Medical Equipment, Supplies & Distribution

Calendar

30/05/2024 - Lytham Partners Spring Investor Conference

More about the company

Income Statement Evolution

More financial data

Ratings for Delcath Systems, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

7.35 USD

Average target price

21.2 USD

Spread / Average Target

+188.44%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Prosthetics

	1st Jan change	Capi.
DELCATH SYSTEMS, INC.	+76.68%	20Cr
SONOVA HOLDING AG	+4.99%	1.89TCr
COCHLEAR LIMITED	+5.32%	1.4TCr
DEMANT A/S	+10.41%	1.04TCr
EYEBRIGHT MEDICAL TECHNOLOGY (BEIJING) CO., LTD.	-17.69%	205.69Cr
EMBLA MEDICAL HF.	+3.10%	176.11Cr
ANGELALIGN TECHNOLOGY INC.	+11.41%	140.92Cr
MODERN DENTAL GROUP LIMITED	+9.07%	57Cr
ANGEL ROBOTICS CO., LTD.	0.00%	42Cr
INTEGRUM AB	+23.99%	9.58Cr

Medical Prosthetics